Trial Profile
A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Bladder cancer; Carcinoma; Malignant melanoma; Ureteral neoplasms; Urethral cancer
- Focus Therapeutic Use
- 10 May 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 10 May 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 09 May 2022 Planned End Date changed from 1 Sep 2022 to 1 Sep 2023.